SG11202108757XA - Methods for treating muscular dystrophy with casimersen - Google Patents

Methods for treating muscular dystrophy with casimersen

Info

Publication number
SG11202108757XA
SG11202108757XA SG11202108757XA SG11202108757XA SG 11202108757X A SG11202108757X A SG 11202108757XA SG 11202108757X A SG11202108757X A SG 11202108757XA SG 11202108757X A SG11202108757X A SG 11202108757XA
Authority
SG
Singapore
Prior art keywords
casimersen
methods
muscular dystrophy
treating muscular
treating
Prior art date
Application number
Other languages
English (en)
Inventor
Edward Kaye
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of SG11202108757XA publication Critical patent/SG11202108757XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202108757X 2019-03-28 2020-03-25 Methods for treating muscular dystrophy with casimersen SG11202108757XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825573P 2019-03-28 2019-03-28
US201962902518P 2019-09-19 2019-09-19
PCT/US2020/024550 WO2020198268A1 (en) 2019-03-28 2020-03-25 Methods for treating muscular dystrophy with casimersen

Publications (1)

Publication Number Publication Date
SG11202108757XA true SG11202108757XA (en) 2021-10-28

Family

ID=70286009

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108757X SG11202108757XA (en) 2019-03-28 2020-03-25 Methods for treating muscular dystrophy with casimersen

Country Status (15)

Country Link
US (2) US20220152086A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946376A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022526763A (cg-RX-API-DMAC7.html)
KR (1) KR20210145192A (cg-RX-API-DMAC7.html)
CN (1) CN113660939A (cg-RX-API-DMAC7.html)
AU (2) AU2020244803A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021018801A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134165A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002437A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014024A2 (cg-RX-API-DMAC7.html)
IL (2) IL318548A (cg-RX-API-DMAC7.html)
MA (1) MA55515A (cg-RX-API-DMAC7.html)
MX (1) MX2021011498A (cg-RX-API-DMAC7.html)
SG (1) SG11202108757XA (cg-RX-API-DMAC7.html)
WO (1) WO2020198268A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
WO2021025899A1 (en) * 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン,ジエ−ムス ポリヌクレオチド測定試薬と方法
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
CA2394758A1 (en) 1999-12-29 2001-07-05 A. James Mixson Histidine-containing copolymers enhance pharmaceutical agent delivery
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
HK1220154A1 (zh) * 2013-03-15 2017-04-28 Sarepta Therapeutics, Inc. 改进的用於治疗肌营养不良的组合物
US20190054113A1 (en) * 2015-09-30 2019-02-21 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
KR20190024977A (ko) * 2016-06-30 2019-03-08 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머
PT4122497T (pt) * 2016-12-19 2024-06-12 Sarepta Therapeutics Inc Conjugados oligoméricos de salto de exão para a distrofia muscular
JP2020536058A (ja) * 2017-09-28 2020-12-10 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーを処置するための併用療法

Also Published As

Publication number Publication date
IL318548A (en) 2025-03-01
MA55515A (fr) 2022-02-09
MX2021011498A (es) 2022-01-04
IL286653A (en) 2021-10-31
US20260007690A1 (en) 2026-01-08
AU2025256263A1 (en) 2025-11-27
EP3946376A1 (en) 2022-02-09
CN113660939A (zh) 2021-11-16
CO2021014024A2 (es) 2021-10-29
JP2022526763A (ja) 2022-05-26
US20220152086A1 (en) 2022-05-19
AU2020244803A1 (en) 2021-11-18
CL2021002437A1 (es) 2022-05-06
CA3134165A1 (en) 2020-10-01
JP2025096396A (ja) 2025-06-26
WO2020198268A1 (en) 2020-10-01
BR112021018801A2 (pt) 2021-11-23
KR20210145192A (ko) 2021-12-01

Similar Documents

Publication Publication Date Title
IL286653A (en) Methods for treating muscular dystrophy with Casimersen
IL272791A (en) Methods for treating muscular dystrophy
GB201903079D0 (en) Process
IL258211A (en) Methods for treating muscular dystrophy
IL307937A (en) Treatment methods for muscular dystrophy
GB201901061D0 (en) Process
GB2586327B (en) Process
GB201916427D0 (en) Process
GB201901069D0 (en) Process
GB201918699D0 (en) Process
GB201902646D0 (en) Process
PL3307065T3 (pl) Komórki chimeryczne związane z dystrofią mięśniową i sposób leczenia dystrofii mięśniowych
GB201905107D0 (en) Process
GB201900940D0 (en) Method
GB201900647D0 (en) Method
GB201913817D0 (en) Process
GB201906768D0 (en) Method
IL282323A (en) Methods for treating (OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD
GB202010889D0 (en) Process
GB2591987B (en) Process
IL274375A (en) Dosing regimen of edsalonacant for the treatment of muscular dystrophy
GB202404562D0 (en) Process
HK40059638A (en) Methods for treating muscular dystrophy with casimersen
GB201906203D0 (en) Method
GB201901532D0 (en) Method